Showing 6431-6440 of 7666 results for "".
- Study: Port Wine Stain Laser Treatment Is Safe and Effective in Infants Without Anesthesiahttps://practicaldermatology.com/news/study-port-wine-stain-laser-treatment-is-safe-and-effective-in-infants-without-anesthesia/2459974/Recent concerns about the repetitive use of general anesthesia in children younger than 3 have placed greater importance on the controversy surrounding the timing of port-wine stain laser treatment, but a new
- FDA Approves Dupixent for Moderate to Severe AD in Adolescentshttps://practicaldermatology.com/news/us-fda-approves-dupixent-for-moderate-to-severe-atopic-dermatitis-in-adolescents/2459975/The FDA has approved expanded use of Regeneron Pharmaceuticals Inc and Sanofi SA's eczema drug Dupixent to include patients aged 12 through 17 whose disease is not adequately controlled with topical prescription
- 2019 NewBeauty Awards: Alastin's TransFORM Body Treatment Acknowledged for Innovationhttps://practicaldermatology.com/news/2019-newbeauty-awards-alastins-transform-body-treatment-acknowledged-for-innovation/2459977/ALASTIN Skincare, Inc’s TransFORM Body Treatment has been awarded a 2019 NewBeauty Award in the innovations category. NewBeauty acknowledges the best products, treatments and trends in cosmetics and aesthetics with their innovation category described as, "the future is now
- Biopelle Launches Emepelle to Address Estrogen Deficient Skinhttps://practicaldermatology.com/news/biopelle-launches-emepelle-to-address-estrogen-deficient-skin/2459979/Biopelle, Inc. has launched Emepelle, the first and only clinically proven skincare line that safely and effectively helps address Estrogen Deficient Skin (EDS). Emepelle features MEP Technology, a patented, specifically designed ingredient that helps
- New Mouse Model Validates How “Good” and “Bad” Bacteria Affect Acnehttps://practicaldermatology.com/news/new-mouse-model-validates-how-good-and-bad-bacteria-affect-acne/2459981/Researchers at University of California San Diego School of Medicine, Cedars-Sinai and UCLA have developed a new mouse model that closely resembles human acne by adding one new factor — a synthetic sebum. Researchers have long believed that Propionibacterium acnes causes ac
- Arkansas Gets SUNucatedhttps://practicaldermatology.com/news/arkansas-gets-sunucated/2459875/Arkansas has joined 18 other states in adopting legislation to allow children to possess and apply sunscreen at school. Governor Asa Hutchinson signed into law HB 1167, which was co-sponsored by Representative Lee Johnson, MD, and carried through the Senate by Senator David Wallace.
- Regenerative Medicine Breakthrough: Mobile Bedside Bioprinter May Heal Woundshttps://practicaldermatology.com/news/regenerative-medicine-breakthrough-mobile-bedside-bioprinter-may-heal-wounds/2459876/Researchers have created a mobile skin bioprinting system that allows bi-layered skin to be printed directly into a wound. The team demonstrated proof-of-concept of the system by printing skin directly onto pre-clinical models, and the next step is to conduct a clinical trial in humans, t
- Meet AAD's New Officers and Board of Directorshttps://practicaldermatology.com/news/meet-aads-new-officers-and-board-of-directors/2459880/The American Academy of Dermatology (AAD) is set to install four new officers and four new members of its board of directors at the conclusion of the 2019 AAD Annual Meeting in Washington. The new members will also hold the same positions for the American Academy of Dermatology Associat
- Dr. George J. Hruza Named New AAD Presidenthttps://practicaldermatology.com/news/dr-george-j-hruza-named-new-aad-president/2459881/St. Louis dermatologist George J. Hruza, MD, MBA, FAAD, is set to begin his one-year term as president of the American Academy of Dermatology (AAD) at the conclusion of the 2019 AAD Annual Meeting in Washington. “The health care landscape is evolving, and it’s important for de
- FDA Approves Janssen's Tremfya One-Presshttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-one-press/2459882/The FDA has approved Tremfya® One-Press, a single-dose, patient-controlled injector for adults with moderate-to-severe plaque psoriasis. Tremfya®(guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson